A year into the Recordati partnership, Amarin's second quarter reads as two stories running in opposite directions. On the surface, total net revenue fell 42% to $42.2 million and a $7.7 million GAAP net loss lingered - the comparison was flattered by a $25.0 million upfront payment from the June 2025 Recordati licensing agreement that did not repeat. Underneath, the operating reset announced at that restructuring is now finished: total operating expenses fell 59% to $27.0 million, and the cost-savings line of the prior year - the $22.8 million restructuring charge itself - is essentially zero. The company generated positive cash flow for the third consecutive quarter, ended the period with $314.6 million in cash and short-term investments against zero debt, and disclosed a current-year cash growth target of roughly 10% versus the December 2025 base. International in-market demand for VASCEPA/VAZKEPA grew 59% year over year across the global partner network, with European in-market demand up 69% and China's in-market volume up 90% year to date. The U.S. franchise - still the revenue anchor - held the company's share of the prescription icosapent-ethyl market at 48%, up from 43% a year ago, and the 14% growth in branded VASCEPA prescriptions during the quarter happened against a 3% expansion of the underlying U.S. IPE category. Management is also working with Barclays as its exclusive financial advisor "to explore additional potential pathways to further enhance shareholder value." The result is a small-cap cardiovascular company in transition: structurally lower-cost, still GAAP-loss-making, debt-free, and trading at a market capitalization of roughly $5.9 billion on $186 million of trailing twelve-month revenue. The thesis is a re-rating bet on a partner-led international expansion layered on top of a stabilized U.S. franchise - with the cash runway giving management the time to let the math work, and a $50 million share repurchase authorization sitting undeployed against a stock that has not yet returned capital.